Vis børsmeldingen
in an online webcast at 10:00am CET.
With reference to the press release issued 1 December 2020 (see link
here (https://www.targovax.com/en/targovax-announces-impressive-objective
-responses-as-well-as-effects-on-non-injected-lesions-in-oncos-102-trial-in-anti
-pd1-refractory-melanoma-patients/)), Targovax will present data from its phase
1 trial combining ONCOS-102 and the anti-PD1 checkpoint inhibitor (CPI)
pembrolizumab (Keytruda) in patients with advanced, unresectable melanoma who
have had disease progression despite treatment with anti-PD1 CPI.
Data from the randomized phase 1/2 trial of ONCOS-102 in combination with
standard-of-care (SoC) chemotherapy in patients with malignant pleural
mesothelioma (MPM), which was released 24 November 2020 (see link
here (https://www.targovax.com/en/targovax-demonstrates-encouraging-survival
-data-for-oncos-102-in-mesothelioma/)), will also be presented in the webcast.
The webcast starts at 10:00am CET and you can join the webcast
here (https://channel.royalcast.com/landingpage/hegnarmedia/20201202_5/). It
will be possible to ask questions during the presentation. A replay of the
webcast will be available in the Investor section under “Presentations” after
the event.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. The Group’s pipeline aims at different
cancer indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.
Further, the products are well positioned for combinations with other treatment
approaches, including other immunotherapies, surgery, radiation and
chemotherapy.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. ONCOS-102 is currently
being tested in mesothelioma, melanoma and colorectal cancer and has already
shown promising clinical results both as monotherapy and in combination with
chemotherapy, and a checkpoint inhibitor.
Kilde